Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Rhythm Pharmaceuticals, Inc. (RYTM)

Caris Life Sciences,�Inc. and Rhythm Pharmaceuticals, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and Rhythm Pharmaceuticals, Inc. are of similar size ($7.4B and $7.3B). Rhythm Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 73.9×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 68.8% against 61.0%. Caris Life Sciences,�Inc. has the higher net margin (9.16% vs −70.6%) and the higher return on invested capital (33.0% vs 0.00%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 15 and Rhythm Pharmaceuticals, Inc. on 2.

Valuation

Metric CAI RYTM Biotechnology median
P/E 73.94 n/m 10.60
P/S 6.80 27.64 9.40
P/B 11.15 88.21 2.13
Price to free cash flow 246.58 n/m 25.18
EV/EBITDA 40.62 n/m 0.66
EV/Sales 6.44 26.50 9.02
Earnings yield 1.35% (2.57%) (32.88%)
Free cash flow yield 0.41% (1.64%) (23.13%)

Profitability

Metric CAI RYTM Biotechnology median
Gross margin 69.09% 88.23% 68.51%
Operating margin 13.35% (66.70%) 0.00%
Net margin 9.16% (70.63%) 0.00%
Free cash flow margin 2.76% (29.13%) 0.00%
Return on equity 17.19% (167.49%) (51.96%)
Return on assets 8.58% (41.75%) (46.06%)
Return on invested capital 32.96% 0.00% 0.00%

Growth

Metric CAI RYTM Biotechnology median
Revenue growth (TTM) 68.84% 61.04% 6.76%
EPS growth (last fiscal year) 69.79% 28.34% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI RYTM Biotechnology median
Debt to equity 0.62 0.00 0.00
Current ratio 6.71 2.78 4.97
Net debt to EBITDA (5.23) 2.04 1.01

Dividend

Metric CAI RYTM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAI RYTM Biotechnology median
Market cap 7.36b 7.28b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack